Molecular Subtyping Can Help Determine Prognosis and Chemotherapy Benefit in Colorectal Cancer Patients
CHICAGO – Molecular subtyping can help predict outcomes and chemotherapy Read More
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
IRVINE, CA, May 31, 2013 – Agendia, a world leader Read More
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
IRVINE, CA, May 2, 2013 – Agendia, a world leader Read More
Study shows half of early-stage breast cancer patients may be able to avoid chemotherapy
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
MammaPrint breast cancer test ID’s women who can avoid chemotherapy
KARE, Minneapolis-St.Paul-2013 This TV report tells how you can “know Read More
Study Shows Half of Early-Stage Breast Cancer Patients May Safely Avoid Chemotherapy
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 4, 2013 – Read More
Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, January 25, 2013 – Read More
Study Indicates Breast Cancer Diagnosis Is More Accurate with New Genomic Tests
SAN ANTONIO – The latest generation of genomic tests for breast Read More
Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
AMSTERDAM, THE NETHERLANDS, and IRVINE, CA, September 13, 2012 – Agendia, an Read More
